Secondary endpoints included changes in (1)
clinical symptom assessment (pain, heaviness, and tension)
via the use of visual analogue scales and (2) assessment of
upper extremity function via the use of the Disabilities of the
Arm, Shoulder and Hand (DASH) Questionnaire [16]. Both
secondary endpoints were evaluated on the 10th treatment
day as well as 3 months following completion of therapy and
compared to baseline.